Recombinant Human uPA Protein (C-6His)

Name: Recombinant Human uPA Protein (C-6His)
Brand: Beta LifeScience
SKU: BL-1330NP
Availability: InStock

BL-1330NP: Greater than 95% as determined by reducing SDS-PAGE. (QC verified)

Collections: All products, High-quality recombinant proteins, Other recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Urokinase-Type Plasminogen Activator is produced by our Mammalian expression system and the target gene encoding Ser21-Leu431 is expressed with a 6His tag at the C-terminus.
Accession	P00749
Synonym	Urokinase-Type Plasminogen Activator; U-Plasminogen Activator; uPA; PLAU
Gene Background	Recombinant Human Urokinase-Type Plasminogen Activator is a serine protease, which specifically cleaves the zymogen plasminogen to form the active enzyme plasmin. Urokinase-Type Plasminogen Activator is a potent marker of invasion and metastasis in many human cancers associated with breast, colon, stomach, bladder, brain, ovary and endometrium. Human Urokinase-Type Plasminogen Activator is initially synthesized as 431 amino acid precursor with a N-terminal signal peptide residues. The single chain molecule is processed into a disulfide-linked two-chain molecule. There exists two forms A chain, the long A chain contains an EGF-like domain that is responsible for binding of the uPA receptor. The B chain corresponds to the catalytic domain.
Molecular Mass	47.41 KDa
Apmol Mass	45-55 KDa, reducing conditions
Formulation	Supplied as a 0.2 μm filtered solution of 20mM HEPES, 2mM CaCl2, 10% Glycerol, pH 7.4.
Endotoxin	Less than 0.1 ng/µg (1 EU/µg) as determined by LAL test.
Purity	Greater than 95% as determined by reducing SDS-PAGE. (QC verified)
Biological Activity	Not tested
Reconstitution
Storage	Store at ≤-70°C, stable for 6 months after receipt. Store at ≤-70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles.
Shipping	The product is shipped on dry ice/polar packs. Upon receipt, store it immediately at the temperature listed below.
Usage	For Research Use Only

Target Details

Target Function	Specifically cleaves the zymogen plasminogen to form the active enzyme plasmin.
Subcellular Location	Secreted.
Protein Families	Peptidase S1 family
Database References	HGNC: 9052 OMIM: 191840 KEGG: hsa:5328 STRING: 9606.ENSP00000361850 UniGene: PMID: 29760745 High Expressions of PLAU is associated with lung adenocarcinoma. PMID: 28454121 Increased expression of uPA in epidermal cells in psoriasis and in tumor cells in basal cell carcinomas suggests an important role of the uPA system for aggressively proliferating and invading cells of epidermal origin. PMID: 28429105 study provides strong support in the role of L. reuteri in suppression of GC cell invasion by downregulation of pathways which is involved in extracellular matrix degradation such as uPA and uPAR PMID: 28643742 Gelsolin enhances the invasive capacity of colon cancer cells via elevating intracellular superoxide (O2.-) levels by interacting with Cu/ZnSOD, and gelsolin gene expression positively correlates with urokinase plasminogen activator (uPA), an important matrix-degrading protease invovled in cancer invasion. PMID: 27391159 Study provides evidence that the stimulation of u-PA/u-PAR system contributes to the activated phenotype and function of cancer-associated fibroblasts during multiple myeloma. PMID: 28340565 OB-Rb, RhoA/ROCK, PI3K/AKT, JAK/STAT pathways and NF-kB activation are involved in leptin-induced upA expression. PMID: 28104444 Results provide evidence that uPA and IGF1R directly interact with uPAR enhancing malignant potential of triple-negative breast cancer. PMID: 27502396 suggest that the low endogenous levels of uPA in blood are actively regulated, and that the regulatory mechanisms are disrupted in QPD in a megakaryocyte-specific manner PMID: 28301587 an intricate link between caveolin-1 and Src kinase-mediated cell signaling and alveolar epithelial cell apoptosis due to loss of SP-C expression through p53 and uPA system-mediated cross-talk, is reported. PMID: 28385810 results show that the uPA/uPAR/LRP1 system is a potential target for the development of therapeutic strategies to promote axonal recovery following a CNS injury PMID: 27986809 The present research concluded that aspirin suppressed prostate cancer cell invasion by reducing MMP-9 activity and uPA expression through decreasing of IKK-beta-mediated NF-kappaB activation, indicating that the ability of aspirin to inhibit cell invasion might be useful in the chemoprevention of metastatic prostate cancer. PMID: 28278500 These studies identify uPA-dependent de-repression of vegfr1 and vegfr2 gene transcription through binding to HHEX/PRH as a novel mechanism by which uPA mediates the pro-angiogenic effects of VEGF and identifies a potential new target for control of pathologic angiogenesis. PMID: 27151212 The up-regulation of uPA mRNAs was correlated with high-risk clinicopathological features, including extrathyroid invasion, loss of cellular polarity/cohesiveness, and the BRAF(V600E) mutation. PMID: 25085839 Transplantation of uPA gene modified mesenchymal stem cells suppressed liver fibrosis and ameliorated liver function and may be a new approach to treating liver fibrosis PMID: 26877613 ApaL1 and Taq1 single nucleotide polymorphisms of the urokinase and VDR genes are associated with recurrent urolithiasis in a Caucasian population. PMID: 26275878 Resveratrol inhibited hypoxia-induced HIF-1alpha protein expression. Resveratrol also suppressed hypoxiainduced expression of metastatic-related factors, uPA and MMP2. PMID: 26707376 Significance of the urokinase-type plasminogen activator and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse models. PMID: 26846181 Data suggest that enhanced levels of uPA in breast cancer modulate the mitogenic effects of EGF which helps to better understand breast cancer pathogenesis. PMID: 25641046 Results found high levels of uPA and uPAR exclusively in metastatic osteosarcoma (OS)cells and suggest that malignant conversion of OS cells to uPA/uPAR axis in an autocrine and paracrine fashion. PMID: 26317203 The morphologically normal tissue adjacent to the tumor shows the substantial expression of MMP-2 and MMP-9 and in some cases the enhanced activity of uPA and ACE, which makes an additional contribution to the increased invasive potential of tumor PMID: 26978018 it was found that the recombinant fusion protein uPA17-34-KPI(kunitz-type protease inhibitor ) inhibited the invasion and metastasis of ovarian tumors PMID: 26166362 Crystal structure of uPA bound with cyclic peptidic inhibitors. PMID: 25744057 u-PA is a dysregulated gene involved in the tumorigenesis, bio-pathological features and outcomes of EEC. PMID: 26033187 High cytoplasmic expression of uPA is associated with cells of rectal cancer and metastases of perienteric lymph nodes. PMID: 26504024 DIM can influence the cell migratory and invasive properties of human colorectal cancer cells and may decrease the invasive capacity of colorectal cancer through downregulation of uPA and MMP9 mediated by suppression of the transcription factor FOXM1 PMID: 25962429 Porphyromonas gingivalis-derived RgpA-Kgp complex activates the macrophage uPA. PMID: 25979345 SNP P141L associated with collateral circulation in coronary artery disease PMID: 24952395 Taking uPA(1-43) amino acids specifically binding to uPAR as targeted part of fusion protein, and making use of antitumor activity of melittin, the recombinant fusion protein it was able to inhibit growth of ovarian tumors . PMID: 25394558 uPA/uPAR stimulates triglyceride synthesis in Huh7 hepatoma cells via p38-dependent upregulation of DGAT2 PMID: 25244504 Studied urokinase-type plasminogen activator regulation in cigarette smoke extract (CSE)-induced EMT in human small airway epithelial cell lines (HSAEpiCs)and in the small airway epithelium of COPD patients. PMID: 25706093 Silencing of ETV4 suppresses invasion of prostate cancer cells by inhibiting the expression of uPA/uPAR as well as (MMP)-2 and MMP-9 PMID: 25544710 miR-193b inhibits the expression of stathmin 1 (STMN1) and urokinase-type plasminogen activator (uPA) in Panc-1 cells. PMID: 25215905 Activation of uPA and MMP-3 in perifocal zone of the tumor can serve as an indexof its invasive activity. PMID: 25993872 These data support the hypothesis that uPA upregulation stimulated by macrophages may play an active role in the onset of osteoarthritis and in the shear-stress protection against this induction. PMID: 23597113 High preprocedural plasma uPA and serum CRP levels are indicative of angina recurrence after successful PTCA, and are valuable for the prognosis of restenosis. PMID: 24057344 Data indicate that urokinase-type plasminogen activator (uPA) activates epithelial sodium channel, gamma subunit (ENaC gamma) through catalytic activity-dependent proteolytic modification. PMID: 25555911 IL-17 may act as chemotropic factor for peripheral blood-Mesenchymal stem cellss by incrementing cell motility and uPA expression during inflammation development. PMID: 25433194 Suggest a possible protective effect of podocyte uPA/uPAR expression against interstitial fibrosis in IgA nephritis. PMID: 24648800 High u-PA expression is associated with metastasis in breast cancer. PMID: 24610082 In human coronary vascular smooth muscle, uPA induces uPAR-independent, domain-dependent smooth muscle cell proliferation through transactivation of EGFR by a plasmin-mediated, ADAM-induced, and HB-EGF-dependent process. PMID: 25082749 IL-33 is involved in u-PA-driven angiogenesis, a process that has been shown before to be linked to inflammation in various pathologies. PMID: 24702774 IL-1beta-induced urokinase plasminogen activator expression via activation of the ERK1/2 and NF-kappaB pathways, which results in invasion of gastric cancer cells. PMID: 24626561 Studied the relationship between uPA gene polymorphisms and clinical manifestations of idiopathic membranous nephropathy. PMID: 24822208 These effects were mediated by the efficient conversion of pro-uPA to active uPA and high phosphorylation levels of ERK detected in the PANC-1 cells expressing exogenous polyserase-1. PMID: 24756697 We found no association between allele frequency and risk of multiples sclerosis for any single nucleotide polymorphism investigated for PLAU PMID: 23897640 results of this study suggest that uPA decreases the removal of HDL-cholesteryl ester in the liver via suppression of the hepatic scavenger receptor class B type I (SR-BI)expression PMID: 24529115 Oncogenic K-Ras and loss of Smad4 mediate invasion by activating an EGFR/NF-kappaB Axis that induces expression of MMP9 and uPA in human pancreas progenitor cells. PMID: 24340014 The findings provide evidence that the rs2227564 C/T SNP in the u-PA gene is associated with the development of oral tongue squamous cell carcinoma. PMID: 23621237 Decreasing uPA levels sensitized cancer cells to TRAIL, leading to markedly increased apoptosis. PMID: 24481457

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.

📧 inquiry@betalifesci.com 📞 +1(201) 888-7983

Contact Us Now for Inquiries, Orders, and Questions

Recombinant Human uPA Protein (C-6His)

Recombinant Human uPA Protein (C-6His)

Product Overview

Target Details

FAQs